Johnson & Johnson Vision Announces FDA Approval of ACUVUE® Abiliti™ Overnight Therapeutic Lenses for

Johnson & Johnson Vision*, a global leader in eye health and part of the Johnson & Johnson Medical Devices Companies†, announced that the U.S. Food and Drug Administration (FDA) has approved ACUVUE® Abiliti™ Overnight Therapeutic Lenses. This is the first and only FDA-approved orthokeratology (ortho-k) contact lens for the management of myopia.

“The FDA approval of Abiliti™ Overnight marks an important milestone in our commitment to help change the trajectory of eye health and reshape the future of children with myopia,” said Xiao-Yu Song, MD, PhD, Global Head of Research & Development, Johnson & Johnson Vision‡. “We look forward to supporting parents and eye care professionals in their care of children with comprehensive resources, starting with Abiliti™ Overnight Therapeutic Lenses, and continuing with additional products and services to address the progression of myopia.”

Myopia is sometimes called ‘nearsightedness’ but it is much more. It is a chronic and progressive disease that poses the biggest eye health threat of the 21st Century1. Young children that are less than 12 years of age and become myopic are the most vulnerable to develop high myopia and can be at increased risk of sight-threatening eye diseases later in life2. Additionally, half of the world’s population is projected to be myopic by 2050 with nearly one billion people expected to have high myopia3.